R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
Trial Parameters
Brief Summary
A single-center, prospective clinical study to evaluate the efficacy and safety of R-CDOP (Rituximab, Cyclophosphamide, Doxorubicin hydrochloride liposome, Vindesine, Prednisone ) in the treatment of newly diagnosed high tumor burden non-Hodgkin's lymphoma, which has previously shown promising efficacy.
Eligibility Criteria
Inclusion Criteria: 1. Histologically immunohistochemistry and imaging confirmed diffuse large B-cell lymphoma or follicular lymphoma grade 3B; 2. Has at least one evaluable or measurable lesion according to Lugano response criteria; 3. Patients with at least one of the following high tumor burden Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm); nodal or extranodal mass \> 7cm in its greater diameter; Hepatomegaly and splenomegaly (infiltration confirmed by PET-CT; Spleen: female \> 15cm, male \> 16cm); Pleural/peritoneal effusion; Lactate dehydrogenase (LDH) three times the upper limit of normal; PET-CT TMTV \>220cm3; 4. Patients previously untreated; 5. Patients aged over 18 and under 75 years; 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0\~2; 7. International Prognostic Index (IPI) score \> 1, or with extranodal mass diameter ≥7cm; 8. Life expectancy ≥ 6 months; 9. Left Ventricular Ejection Fraction (LVEF) ≥ 50%; 10. Patients m